10:13:30 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-08-14 Kvartalsrapport 2024-Q2
2024-03-07 X-dag ordinarie utdelning DEMANT 0.00 DKK
2024-03-06 Årsstämma 2024
2024-02-06 Bokslutskommuniké 2023
2023-08-15 Kvartalsrapport 2023-Q2
2023-03-09 X-dag ordinarie utdelning DEMANT 0.00 DKK
2023-03-08 Årsstämma 2023
2023-02-07 Bokslutskommuniké 2022
2022-08-16 Kvartalsrapport 2022-Q2
2022-03-11 X-dag ordinarie utdelning DEMANT 0.00 DKK
2022-03-10 Årsstämma 2022
2022-02-08 Bokslutskommuniké 2021
2021-08-12 Kvartalsrapport 2021-Q2
2021-03-08 X-dag ordinarie utdelning DEMANT 0.00 DKK
2021-03-05 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-08-17 Kvartalsrapport 2020-Q2
2020-03-11 X-dag ordinarie utdelning DEMANT 0.00 DKK
2020-03-10 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q2
2019-03-20 X-dag ordinarie utdelning DEMANT 0.00 DKK
2019-03-19 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-08-15 Kvartalsrapport 2018-Q2
2018-03-23 X-dag ordinarie utdelning DEMANT 0.00 DKK
2018-03-22 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-08-14 Kvartalsrapport 2017-Q2
2017-05-09 Kvartalsrapport 2017-Q1
2017-03-28 X-dag ordinarie utdelning DEMANT 0.00 DKK
2017-03-27 Årsstämma 2017
2017-02-23 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-25 Split DEMANT 1:5
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-08 X-dag ordinarie utdelning DEMANT 0.00 DKK
2016-04-07 Årsstämma 2016
2016-03-01 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-14 Kvartalsrapport 2015-Q2
2015-05-07 Kvartalsrapport 2015-Q1
2015-04-10 X-dag ordinarie utdelning DEMANT 0.00 DKK
2015-04-09 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2014-11-13 Kvartalsrapport 2014-Q3
2014-08-14 Kvartalsrapport 2014-Q2
2014-05-08 Kvartalsrapport 2014-Q1
2014-04-10 X-dag ordinarie utdelning DEMANT 0.00 DKK
2014-04-09 Årsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-11-05 Kvartalsrapport 2013-Q3
2013-08-14 Kvartalsrapport 2013-Q2
2013-05-07 Kvartalsrapport 2013-Q1
2013-04-10 X-dag ordinarie utdelning DEMANT 0.00 DKK
2013-04-09 Årsstämma 2013
2013-02-26 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-05-10 Kvartalsrapport 2012-Q1
2012-04-12 X-dag ordinarie utdelning DEMANT 0.00 DKK
2012-04-11 Årsstämma 2012
2012-02-29 Bokslutskommuniké 2011
2011-11-10 Kvartalsrapport 2011-Q3
2011-08-19 Kvartalsrapport 2011-Q2
2011-05-12 Kvartalsrapport 2011-Q1
2011-04-14 X-dag ordinarie utdelning DEMANT 0.00 DKK
2011-04-13 Årsstämma 2011
2010-11-16 Kvartalsrapport 2010-Q3
2010-04-08 X-dag ordinarie utdelning DEMANT 0.00 DKK


ListaLarge Cap Copenhagen
Demant är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av hörapparater och hörslingor. Idag innehar bolaget verksamhet på global nivå där produkterna säljs under varierande varumärken. Produkterna nås via bolagets distributörer och försäljningskanaler. Utöver huvudverksamheten bedriver bolaget forskning inom diagnostik för mätning av hörselkvalitén. Bolaget grundades ursprungligen under 1904 och har sitt huvudkontor i Smörum.
2024-03-12 07:30:34

12.3.2024 07:30:32 CET | Demant A/S | Investor News

Investor news                                                        12 March 2024

Capital Markets Day 2024

Sharpened focus on Hearing Healthcare


On Tuesday, 12 March 2024, at 11:00 CET, Demant hosts a Capital Markets Day (CMD) at our headquarters in Smørum, Denmark, for investors and analysts. During the event, we will outline our strategic priorities and financial aspirations for the medium to long term and also deep dive into how we deliver market-leading innovation and further expand our distribution going forward. The presentations and a livestream will be available on our website shortly before the event.



Since our latest CMD in 2021, Demant has undergone significant strategic changes. Following the decisions to discontinue our Hearing Implants business area and to undertake a strategic review of Communications, we are now emerging as a more focused and more profitable company. This allows us to be fully focused on our core Hearing Healthcare business and by doing so to continue to grow our market share by delivering market-leading innovation, further expand our distribution and thus enable us to reach and help even more people hear better.


Key messages from today’s Capital Markets Day

Under the theme, Sharpened focus on Hearing Healthcare, the key messages from today’s Capital Markets Day will be:


  • We upgrade our view on the hearing aid market, which we now expect to grow 4-6% p.a. in value (previously 2-5% p.a.), reflecting annual unit growth of 4-6% and flattish yearly ASP development (previously negative by 1-2% p.a.), which is in line with the estimated recent historical ASP development. For the hearing healthcare market, which also includes the market for diagnostic equipment, we thus expect annual value growth of around 5% (previously 4%).
  • Our medium- to long-term outlook now relates to our Hearing Aids, Hearing Care and Diagnostics business areas, collectively our Hearing Healthcare business. Driven by our more positive view on the hearing healthcare market and our aspiration of continued market share gains, we aim for annual revenue growth of 8-10% in local currencies, which comprises organic growth of 6-8 percentage points and growth from bolt-on acquisitions of around 2 percentage points.
  • Over the medium to long term, we expect incremental EBIT margin expansion, and we consider scale a significant parameter for delivering improved profitability.
  • Innovation remains at the core of our company, and we believe that being leaders in audiological performance is an important part of sustaining a competitive advantage in our industry. As we go forward, we are committed to continuing to invest in next-generation hearing healthcare solutions using groundbreaking sound-processing based on deep neural networks and other advances in artificial intelligence.
  • We still believe strongly in the value of professional, in-person counselling and care for patients through either external customers or our own Hearing Care network. We will continue to invest in global distribution, including continued expansion of Hearing Care both organically and through acquisitions, to further increase the scale and profitability of our Group.
  • We remain a highly cash-generative business, and despite continuous value-adding investments in R&D and distribution, we expect free cash flow generation to remain strong going forward, leaving ample room for cash returns to shareholders in the form of share buy-backs. Our gearing multiple target remains unchanged at 2.0-2.5.
  • We are a positive-impact business and employ sustainable business practices as an integrated part of our strategy. Over the last years, we have seen a steady improvement of our ESG performance, and we remain committed to enhancing our sustainability efforts both in terms of disclosure and by delivering on our targets within climate and diversity, equity and inclusion.




Peter Pudselykke

Head of Investor Relations


Sharpened focus on Hearing Healthcare

Søren Nielsen

President & CEO


Lunch break and product demos



Fuelling innovation and core technology development in Hearing Aids

Various speakers from Hearing Aids


Break and product demos



Succeeding in the US hearing aid market

Ty Lee

President, Hearing Aids

North America


Continuing our Hearing Care growth journey

Niels Wagner

President, Hearing Care





Driving scale benefits to deliver long-term shareholder value

René Schneider



Final Q&A and concluding remarks



End of event



Outlook for 2024 announced in February remains unchanged

2024 has been off to a good start in line with expectations, and we reiterate our outlook for the year of organic growth of 4-8%, EBIT of DKK 4,600-5,000 million and share buy-backs of more than DKK 2,000 million.


For our discontinued business areas, we still expect the divestment of our cochlear implants business to close in H1 2024, as the process is progressing according to plan. The bone-anchored hearing systems business will remain with the Group for now, pending a review of our strategic options. The strategic review of Communications is still ongoing as planned, and we expect it to be concluded by the end of H1 2024.


Practical matters

For in-person attendance, registration will open at 10:30 CET. The event will start at 11:00 CET at our headquarters in Smørum, Denmark. The presentations and livestream will be available on our website shortly before the event, and a replay will also be made available on our website following the event. Throughout the day, there will be Q&A sessions after each presentation. However, it is only possible to ask questions live from the venue.



Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300


Other contacts:

René Schneider, CFO

Peter Pudselykke, Head of Investor Relations

Henrik Axel Lynge Buchter, Manager of External Communication



  • Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.